GlaxoSmithKline acquires generics business of Bristol Myers Squibb
GSK | Quote | Chart | News | PowerRating -- GlaxoSmithKline plc (GSK), a UK-based pharmaceutical and healthcare company, has acquired the branded generics business of Bristol-Myers Squibb Company in Lebanon, Jordan, Syria, Libya, and Yemen for GBP14.2 million in cash. The business comprises a portfolio of 13 branded pharmaceuticals. Bristol-Myers Squibb is a US-based pharmaceuticals company.
BMS will continue to supply the acquired products until 2011 when it is anticipated that manufacture will transfer to GSK's Giza plant.
Deal Value (US$ Million) 23.2
Deal Type Acquisition
Sub-Category Asset Purchase
Deal Status Completed: 2009-07-02
Deal Participants
Target (Company) Bristol-Myers Squibb Company - Generics Business
Acquirer (Company) GlaxoSmithKline plc
Vendor (Company) Bristol-Myers Squibb Company
Deal Rationale
The acquisition represents GSK's strategy to accelerate growth in the emerging markets and extends its product portfolio in the Middle East and North Africa.
For full details on GlaxoSmithKline (GSK) GSK. GlaxoSmithKline (GSK) has Short Term PowerRatings at TradingMarkets. Details on GlaxoSmithKline (GSK) Short Term PowerRatings is available at This Link.
For full details on Bristol-Myers Squibb Co (BMY) BMY. Bristol-Myers Squibb Co (BMY) has Short Term PowerRatings at TradingMarkets. Details on Bristol-Myers Squibb Co (BMY) Short Term PowerRatings is available at This Link.
- KineMed Strengthens Collaboration with Bristol-Myers Squibb - 02/10/10
- Zacks Sell List Highlights: BancorpSouth, Inc., Aetna Inc., GlaxoSmithKline plc and Airgas, Inc. - 02/09/10
- Research and Markets: Bristol-Myers Squibb Co. - Company PicShot: All That You Need To Know About a Company in a Comprehensively - 02/09/10
- Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results - 02/09/10
- KineMed broadens collaboration with Bristol-Myers - 02/09/10
- More News >>


